Payment overview · 2025
General Payments
$155.87
7 reported records · 6 companies
Healthcare provider profile · identity verified
Litai Chuo, MD
Allopathic & Osteopathic Physicians|Family Medicine · GEORGETOWN, TX · NPI 1841384211
Verified facts
What the public records show
CMS Open Payments records show Litai Chuo, MD received $155.87 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.67 | 22.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.51 | 20.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.90 | 19.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.28 | 16.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.20 | 12.3% | 1 | 2025 |
| Spinal Simplicity, LLC | Unresolved — no canonical attribution shown | $14.31 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $155.87 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| HA MINUTEMAN G3-R Normalized: ha minuteman g3 r |
Device | Spinal Simplicity, LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 84 |
| Metformin Hcl | Metformin Hcl | 199 | 62 |
| Lisinopril | Lisinopril | 194 | 61 |
| Losartan Potassium | Losartan Potassium | 174 | 54 |
| Ozempic | Semaglutide | 130 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 42 |
| Gabapentin | Gabapentin | 111 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 36 |
| Omeprazole | Omeprazole | 104 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 28 |
| Simvastatin | Simvastatin | 88 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 27 |
| Metformin Hcl Er | Metformin Hcl | 61 | 19 |
| Glimepiride | Glimepiride | 52 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Trazodone Hcl | Trazodone Hcl | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 12 |
| Montelukast Sodium | Montelukast Sodium | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 18 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 12 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Azithromycin | Azithromycin | 37 | 33 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Tramadol Hcl | Tramadol Hcl | 31 | 19 |
| Meloxicam | Meloxicam | 30 | 13 |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 15 |
| Furosemide | Furosemide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Prednisone | Prednisone | 25 | 13 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.87 · 7 records | Amgen Inc. | ELIQUIS, HA MINUTEMAN G3-R, INSPIRE, KRYSTEXXA, NURTEC ODT, OTEZLA, PROCLAIM, QULIPTA, REPATHA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error